{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:35:36Z","timestamp":1789526136775,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T00:00:00Z","timestamp":1431475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.ejca.2015.05.009","type":"journal-article","created":{"date-parts":[[2015,5,26]],"date-time":"2015-05-26T00:07:10Z","timestamp":1432598830000},"page":"1611-1617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery"],"prefix":"10.1016","volume":"51","author":[{"given":"H.","family":"Joensuu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Martin-Broto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Reichardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.G.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2015.05.009_b0005","doi-asserted-by":"crossref","first-page":"e20294","DOI":"10.1371\/journal.pone.0020294","article-title":"Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing","volume":"6","author":"Ducimeti\u00e8re","year":"2011","journal-title":"PLoS One"},{"issue":"9896","key":"10.1016\/j.ejca.2015.05.009_b0010","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0140-6736(13)60106-3","article-title":"Gastrointestinal stromal tumour","volume":"382","author":"Joensuu","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejca.2015.05.009_b0015","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archsurg.2009.108","article-title":"An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system","volume":"144","author":"Woodall","year":"2009","journal-title":"Arch Surg"},{"issue":"12","key":"10.1016\/j.ejca.2015.05.009_b0020","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc3143","article-title":"Gastrointestinal stromal tumours: origin and molecular oncology","volume":"11","author":"Corless","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"9669","key":"10.1016\/j.ejca.2015.05.009_b0025","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","article-title":"Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"DeMatteo","year":"2009","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejca.2015.05.009_b0030","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","article-title":"Twelve vs. 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence. Final results of a randomized trial (SSGXVIII\/AIO)","volume":"307","author":"Joensuu","year":"2012","journal-title":"JAMA"},{"issue":"15s","key":"10.1016\/j.ejca.2015.05.009_b0035","first-page":"632s","article-title":"Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC\/AGITG\/FSG\/GEIS\/ISG randomized controlled Phase III trial","volume":"31","author":"Casali","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.05.009_b0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","article-title":"Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts","volume":"13","author":"Joensuu","year":"2012","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2015.05.009_b0045","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2015.05.009_b0050","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2015.05.009_b0055","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/cncr.23199","article-title":"Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)","volume":"112","author":"DeMatteo","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2015.05.009_b0060","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.pas.0000146010.92933.de","article-title":"Gastrointestinal stromal tumors of the stomach. A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up","volume":"29","author":"Miettinen","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ejca.2015.05.009_b0065","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00000478-200604000-00008","article-title":"Gastrointestinal stromal tumors of the jejunum and ileum. A clinopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term-follow-up","volume":"30","author":"Miettinen","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.ejca.2015.05.009_b0070","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.humpath.2008.06.025","article-title":"Risk stratification of patients diagnosed with gastrointestinal stromal tumor","volume":"39","author":"Joensuu","year":"2008","journal-title":"Hum Pathol"},{"issue":"15S","key":"10.1016\/j.ejca.2015.05.009_b0075","first-page":"548","article-title":"Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST)","volume":"27","author":"Hohenberger","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2015.05.009_b0080","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","article-title":"Gastrointestinal stromal tumors: pathology and prognosis at different sites","volume":"23","author":"Miettinen","year":"2006","journal-title":"Semin Diagn Pathol"},{"issue":"11","key":"10.1016\/j.ejca.2015.05.009_b0085","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1097\/PAS.0b013e3182986b88","article-title":"Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing","volume":"37","author":"K\u00fcnstlinger","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.ejca.2015.05.009_b0090","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ijc.11323","article-title":"Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors","volume":"106","author":"Wardelmann","year":"2003","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2015.05.009_b0095","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/annonc\/mdq047","article-title":"Prognostic time dependence of deletions affecting codons 557 and\/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study","volume":"21","author":"Martin-Broto","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2015.05.009_b0100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/annonc\/mdr127","article-title":"Prognostic value of KIT\/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical Registry experience","volume":"23","author":"Wozniak","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2015.05.009_b0105","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2014.57.4970","article-title":"KIT and PDGFRA mutations and the risk of gastrointestinal stromal tumor recurrence","volume":"33","author":"Joensuu","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2015.05.009_b0110","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/1078-0432.CCR-11-1610","article-title":"Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors","volume":"18","author":"Lagarde","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.ejca.2015.05.009_b0115","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/cncr.28669","article-title":"Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib","volume":"120","author":"Joensuu","year":"2014","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.ejca.2015.05.009_b0120","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.2013.51.2046","article-title":"Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial","volume":"32","author":"Corless","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2015.05.009_b0125","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1148\/radiol.13131040","article-title":"Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients","volume":"271","author":"Joensuu","year":"2014","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.ejca.2015.05.009_b0130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","article-title":"Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival","volume":"231","author":"DeMatteo","year":"2000","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ejca.2015.05.009_b0135","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12254-014-0146-8","article-title":"Follow-up of soft tissue sarcomas","volume":"7","author":"Rutkowski","year":"2014","journal-title":"Memo"},{"key":"10.1016\/j.ejca.2015.05.009_b0140","doi-asserted-by":"crossref","first-page":"d947","DOI":"10.1136\/bmj.d947","article-title":"The risks of radiation exposure related to diagnostic imaging and how to minimise them","volume":"342","author":"Davies","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ejca.2015.05.009_b0145","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00423-008-0449-5","article-title":"Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients < or = 40 years: an overview based on our case material and the literature","volume":"394","author":"Agaimy","year":"2009","journal-title":"Langenbecks Arch Surg"},{"issue":"4","key":"10.1016\/j.ejca.2015.05.009_b0150","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/PAS.0b013e31820e5f7d","article-title":"\u201cPediatric-type\u201d gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior","volume":"35","author":"Rege","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2015.05.009_b0155","unstructured":"National Comprehensive Cancer Network guidelines Version 2. Center <http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf>; 2014 (visited on Jan 29, 2015)."},{"issue":"Suppl. 3","key":"10.1016\/j.ejca.2015.05.009_b0160","doi-asserted-by":"crossref","first-page":"iii21","DOI":"10.1093\/annonc\/mdu255","article-title":"Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"ESMO\/European Sarcoma Network Working Group","year":"2014","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.ejca.2015.05.009_b0165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.13-S2-4","article-title":"Response evaluation of gastrointestinal stromal tumors","volume":"13","author":"Choi","year":"2008","journal-title":"Oncologist"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915003950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915003950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,25]],"date-time":"2019-08-25T14:32:36Z","timestamp":1566743556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915003950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0959804915003950"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.05.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}